vs

Side-by-side financial comparison of Armour Residential REIT, Inc. (ARR) and Axogen, Inc. (AXGN). Click either name above to swap in a different company.

Axogen, Inc. is the larger business by last-quarter revenue ($61.5M vs $50.4M, roughly 1.2× Armour Residential REIT, Inc.). Armour Residential REIT, Inc. runs the higher net margin — 420.2% vs -31.9%, a 452.1% gap on every dollar of revenue. On growth, Armour Residential REIT, Inc. posted the faster year-over-year revenue change (297.9% vs 26.6%). Over the past eight quarters, Armour Residential REIT, Inc.'s revenue compounded faster (108.0% CAGR vs 13.3%).

Armour Residential REIT, Inc. is a U.S.-based real estate investment trust that primarily invests in agency residential mortgage-backed securities guaranteed by U.S. government-sponsored entities. It focuses on generating consistent long-term net income for shareholders via strategic asset management and active interest rate risk mitigation.

Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is...

ARR vs AXGN — Head-to-Head

Bigger by revenue
AXGN
AXGN
1.2× larger
AXGN
$61.5M
$50.4M
ARR
Growing faster (revenue YoY)
ARR
ARR
+271.3% gap
ARR
297.9%
26.6%
AXGN
Higher net margin
ARR
ARR
452.1% more per $
ARR
420.2%
-31.9%
AXGN
Faster 2-yr revenue CAGR
ARR
ARR
Annualised
ARR
108.0%
13.3%
AXGN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ARR
ARR
AXGN
AXGN
Revenue
$50.4M
$61.5M
Net Profit
$211.7M
$-19.6M
Gross Margin
75.2%
Operating Margin
20.2%
Net Margin
420.2%
-31.9%
Revenue YoY
297.9%
26.6%
Net Profit YoY
555.9%
-410.8%
EPS (diluted)
$2.43
$-0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARR
ARR
AXGN
AXGN
Q1 26
$61.5M
Q4 25
$50.4M
$59.9M
Q3 25
$38.5M
$60.1M
Q2 25
$33.1M
$56.7M
Q1 25
$36.3M
$48.6M
Q4 24
$12.7M
$49.4M
Q3 24
$48.6M
Q2 24
$7.0M
$47.9M
Net Profit
ARR
ARR
AXGN
AXGN
Q1 26
$-19.6M
Q4 25
$211.7M
$-13.2M
Q3 25
$159.3M
$708.0K
Q2 25
$-75.6M
$579.0K
Q1 25
$27.3M
$-3.8M
Q4 24
$-46.4M
$450.0K
Q3 24
$-1.9M
Q2 24
$-48.4M
$-1.9M
Gross Margin
ARR
ARR
AXGN
AXGN
Q1 26
75.2%
Q4 25
74.1%
Q3 25
76.6%
Q2 25
74.2%
Q1 25
71.9%
Q4 24
76.1%
Q3 24
74.9%
Q2 24
73.8%
Operating Margin
ARR
ARR
AXGN
AXGN
Q1 26
20.2%
Q4 25
-16.3%
Q3 25
3.2%
Q2 25
3.0%
Q1 25
-3.4%
Q4 24
4.1%
Q3 24
-0.6%
Q2 24
-0.9%
Net Margin
ARR
ARR
AXGN
AXGN
Q1 26
-31.9%
Q4 25
420.2%
-22.0%
Q3 25
413.5%
1.2%
Q2 25
-228.4%
1.0%
Q1 25
75.2%
-7.9%
Q4 24
-366.8%
0.9%
Q3 24
-3.8%
Q2 24
-693.8%
-4.0%
EPS (diluted)
ARR
ARR
AXGN
AXGN
Q1 26
$-0.38
Q4 25
$2.43
$-0.28
Q3 25
$1.49
$0.01
Q2 25
$-0.94
$0.01
Q1 25
$0.32
$-0.08
Q4 24
$-0.91
$-0.00
Q3 24
$-0.04
Q2 24
$-1.05
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARR
ARR
AXGN
AXGN
Cash + ST InvestmentsLiquidity on hand
$63.3M
$82.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.3B
$244.8M
Total Assets
$21.0B
$289.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARR
ARR
AXGN
AXGN
Q1 26
$82.7M
Q4 25
$63.3M
$41.5M
Q3 25
$44.2M
$35.8M
Q2 25
$141.2M
$29.9M
Q1 25
$49.1M
$22.1M
Q4 24
$68.0M
$33.5M
Q3 24
$24.5M
Q2 24
$126.6M
$21.1M
Total Debt
ARR
ARR
AXGN
AXGN
Q1 26
Q4 25
$48.4M
Q3 25
$48.2M
Q2 25
$47.9M
Q1 25
$47.7M
Q4 24
$47.5M
Q3 24
$47.3M
Q2 24
$47.0M
Stockholders' Equity
ARR
ARR
AXGN
AXGN
Q1 26
$244.8M
Q4 25
$2.3B
$128.8M
Q3 25
$2.1B
$120.8M
Q2 25
$1.7B
$112.3M
Q1 25
$1.7B
$105.4M
Q4 24
$1.4B
$103.9M
Q3 24
$99.4M
Q2 24
$1.2B
$95.7M
Total Assets
ARR
ARR
AXGN
AXGN
Q1 26
$289.5M
Q4 25
$21.0B
$221.7M
Q3 25
$19.4B
$216.4M
Q2 25
$16.2B
$205.5M
Q1 25
$15.5B
$196.2M
Q4 24
$13.5B
$203.7M
Q3 24
$192.0M
Q2 24
$10.1B
$188.9M
Debt / Equity
ARR
ARR
AXGN
AXGN
Q1 26
Q4 25
0.38×
Q3 25
0.40×
Q2 25
0.43×
Q1 25
0.45×
Q4 24
0.46×
Q3 24
0.48×
Q2 24
0.49×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARR
ARR
AXGN
AXGN
Operating Cash FlowLast quarter
$124.2M
Free Cash FlowOCF − Capex
$-1.4M
FCF MarginFCF / Revenue
-2.3%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.59×
TTM Free Cash FlowTrailing 4 quarters
$9.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARR
ARR
AXGN
AXGN
Q1 26
Q4 25
$124.2M
$3.0M
Q3 25
$-37.8M
$3.2M
Q2 25
$25.0M
$7.7M
Q1 25
$101.5M
$-13.2M
Q4 24
$261.5M
$8.7M
Q3 24
$3.9M
Q2 24
$27.1M
$4.2M
Free Cash Flow
ARR
ARR
AXGN
AXGN
Q1 26
$-1.4M
Q4 25
$1.8M
Q3 25
$1.7M
Q2 25
$7.0M
Q1 25
$-13.4M
Q4 24
$8.1M
Q3 24
$3.3M
Q2 24
$3.3M
FCF Margin
ARR
ARR
AXGN
AXGN
Q1 26
-2.3%
Q4 25
3.0%
Q3 25
2.8%
Q2 25
12.4%
Q1 25
-27.7%
Q4 24
16.3%
Q3 24
6.8%
Q2 24
6.8%
Capex Intensity
ARR
ARR
AXGN
AXGN
Q1 26
Q4 25
2.1%
Q3 25
2.5%
Q2 25
1.3%
Q1 25
0.5%
Q4 24
1.4%
Q3 24
1.2%
Q2 24
1.9%
Cash Conversion
ARR
ARR
AXGN
AXGN
Q1 26
Q4 25
0.59×
Q3 25
-0.24×
4.55×
Q2 25
13.35×
Q1 25
3.71×
Q4 24
19.41×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons